跳至主要内容

How to ensure data quality and accuracy in non-clinical data exchange?

 


Ensuring data quality and accuracy in non-clinical data exchange requires multi-party collaboration and implementation of measures. It is very important to ensure the quality and accuracy of data in non-clinical data exchange. Here are some suggestions and methods:

1. Define clear data quality standards: Before data exchange begins, participants should clarify data quality standards, including requirements for data integrity, accuracy, consistency, authenticity, and legality. These standards should be consistent with the purposes of data exchange and the requirements for data use.

2. Data quality inspection: During the data exchange process, participants should conduct data quality inspection, including inspection of data integrity, accuracy, consistency and legality. These checks can be performed manually or using automated tools.

3. Data verification and verification: After receiving the data, the receiving party should verify and verify the data to ensure that the data meets quality standards. These verifications and verifications can include inspections of data format, content, logical relationships, etc., as well as comparisons with other data sources.

4. Use standardized data processing methods: Participants should adopt standardized data processing methods to ensure the consistency and accuracy of the data processing process. This includes standardized processes and methods for data cleaning, organization, and analysis.

5. Training and personnel quality improvement: Participants should provide training and personnel quality improvement plans to ensure that staff have the necessary data processing skills and knowledge and can understand and comply with data quality standards and data processing procedures.

6. Establish a data quality monitoring and improvement mechanism: Participants should establish a data quality monitoring and improvement mechanism, regularly assess the quality and accuracy of data, and discover and solve data quality problems. This includes mechanisms for establishing data quality assessment indicators, conducting regular data quality assessments, and tracking and resolving data quality issues.

7. Establish communication mechanisms and collaboration processes: Participants should establish effective communication mechanisms and collaboration processes to ensure timely communication and resolution of data quality and data processing issues between parties. This includes measures such as holding regular meetings, establishing communication channels, and developing collaboration processes.

In short, ensuring data quality and accuracy in non-clinical data exchange requires joint efforts and collaboration from all parties, including defining clear data quality standards, conducting data quality inspections, adopting standardized data processing methods, training and personnel quality improvement, Establish data quality monitoring and improvement mechanisms as well as establish communication mechanisms and collaboration processes.

评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

  Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the   preclinical study   of the antibody-drug-conjugate (ADC)  DXC005, including the   pharmacology study ,   DMPK study   and the   safety evaluation . Medicilon has previously completed integrated  preclinical research  on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...